We are live on ! Find out more
ELVN icon

Enliven Therapeutics
ELVN

40 hedge funds and large institutions have $92.6M invested in Enliven Therapeutics in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

30% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 10

21% more funds holding

Funds holding: 33 → 40 (+7)

1.09% less ownership

Funds ownership: 16.74% → 15.65% (-1.1%)

64% less capital invested

Capital invested by funds: $257M → $92.6M (-$164M)

Holders
40
Holders Change
+7
Holders Change %
+21.21%
% of All Funds
0.7%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
13
Reduced
10
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$3.99M
2
Two Sigma Investments
Two Sigma Investments
New York
+$647K
3
Bank of America
Bank of America
North Carolina
+$569K
4
Walleye Capital
Walleye Capital
New York
+$428K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$255K

Top Sellers

Rank Fund Capital Flow
1
RSCM
Rock Springs Capital Management
Maryland
-$7.95M
2
DM
Deerfield Management
New York
-$6.33M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.63M
4
SFI
Susquehanna Fundamental Investments
Pennsylvania
-$206K
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$104K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$33.9M – – –
O
2
OrbiMed
New York
$23M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$19M -$4.63M -91,143 -14%
BlackRock
4
BlackRock
New York
$3.85M +$159K +3,134 +3%
Morgan Stanley
5
Morgan Stanley
New York
$2.72M +$3.99M +78,531 +3,829%
RCM
6
RA Capital Management
Massachusetts
$2.1M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$1.94M +$255K +5,017 +10%
State Street
8
State Street
Massachusetts
$933K +$67.1K +1,320 +5%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$885K +$33.6K +661 +3%
DM
10
Deerfield Management
New York
$671K -$6.33M -124,601 -86%
Northern Trust
11
Northern Trust
Illinois
$657K -$55.8K -1,098 -5%
Two Sigma Investments
12
Two Sigma Investments
New York
$430K +$647K +12,732 New
Bank of America
13
Bank of America
North Carolina
$396K +$569K +11,189 +2,005%
Charles Schwab
14
Charles Schwab
California
$285K -$17.7K -349 -4%
JP Morgan Chase
15
JP Morgan Chase
New York
$177K +$6.3K +124 +2%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$153K -$104K -2,043 -31%
Millennium Management
17
Millennium Management
New York
$148K +$203 +4 +0.1%
Two Sigma Advisers
18
Two Sigma Advisers
New York
$139K +$210K +4,125 New
California Public Employees Retirement System
19
California Public Employees Retirement System
California
$135K -$19K -374 -9%
Walleye Trading
20
Walleye Trading
New York
$133K +$200K +3,945 New
N
21
Nuveen
North Carolina
$126K +$189K +3,728 New
LJAC
22
L.J. Altfest & Co
New York
$126K +$190K +3,735 New
Jacobs Levy Equity Management
23
Jacobs Levy Equity Management
New Jersey
$116K +$175K +3,449 New
Goldman Sachs
24
Goldman Sachs
New York
$108K +$162K +3,186 New
ASN
25
Advisory Services Network
Georgia
$99K +$148K +2,920 New
1
2

ELVN Hedge Fund Activity: Q1 2021 in Review

40 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q1 2021, worth a combined $92.6M — down 64% from $257M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new ELVN positions and 3 closed out — a net gain of 7 holders — while 13 added to existing stakes and 10 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $3.99M. The largest seller was Rock Springs Capital Management, exiting entirely with an estimated $7.95M sold.

  • 40 institutional investors held Enliven Therapeutics (ELVN) as of Q1 2021, up from 33 in Q4 2020.
  • Funds reported $92.6M of Enliven Therapeutics stock for Q1 2021, down 64% quarter-over-quarter.
  • 10 funds opened new Enliven Therapeutics positions in Q1 2021 and 3 closed out, a net change of +7 holders.
  • The largest Enliven Therapeutics buyer in Q1 2021 was Morgan Stanley, an estimated $3.99M added.
  • The largest Enliven Therapeutics seller in Q1 2021 was Rock Springs Capital Management, an estimated $7.95M sold.

Based on aggregated 13F filings for Q1 2021.